293 related articles for article (PubMed ID: 11280783)
1. Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone.
Yonou H; Yokose T; Kamijo T; Kanomata N; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
Cancer Res; 2001 Mar; 61(5):2177-82. PubMed ID: 11280783
[TBL] [Abstract][Full Text] [Related]
2. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
[TBL] [Abstract][Full Text] [Related]
3. A metastatic human prostate cancer model using intraprostatic implantation of tumor produced by PC-3 neolacZ transfected cells.
Tsingotjidou AS; Ahluwalia R; Zhang X; Conrad H; Emmanouilides C
Int J Oncol; 2003 Dec; 23(6):1569-74. PubMed ID: 14612928
[TBL] [Abstract][Full Text] [Related]
4. A Nod Scid mouse model to study human prostate cancer.
Bastide C; Bagnis C; Mannoni P; Hassoun J; Bladou F
Prostate Cancer Prostatic Dis; 2002; 5(4):311-5. PubMed ID: 12627217
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors.
Goya M; Miyamoto S; Nagai K; Ohki Y; Nakamura K; Shitara K; Maeda H; Sangai T; Kodama K; Endoh Y; Ishii G; Hasebe T; Yonou H; Hatano T; Ogawa Y; Ochiai A
Cancer Res; 2004 Sep; 64(17):6252-8. PubMed ID: 15342412
[TBL] [Abstract][Full Text] [Related]
6. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.
Yonou H; Kanomata N; Goya M; Kamijo T; Yokose T; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
Cancer Res; 2003 May; 63(9):2096-102. PubMed ID: 12727825
[TBL] [Abstract][Full Text] [Related]
7. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice.
Pettaway CA; Pathak S; Greene G; Ramirez E; Wilson MR; Killion JJ; Fidler IJ
Clin Cancer Res; 1996 Sep; 2(9):1627-36. PubMed ID: 9816342
[TBL] [Abstract][Full Text] [Related]
8. Comparative intraosseal growth of human prostate cancer cell lines LNCaP and PC-3 in the nude mouse.
Soos G; Jones RF; Haas GP; Wang CY
Anticancer Res; 1997; 17(6D):4253-8. PubMed ID: 9494517
[TBL] [Abstract][Full Text] [Related]
9. Intraosseous growth of human prostate cancer in implanted adult human bone: relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions.
Yonou H; Ochiai A; Goya M; Kanomata N; Hokama S; Morozumi M; Sugaya K; Hatano T; Ogawa Y
Prostate; 2004 Mar; 58(4):406-13. PubMed ID: 14968441
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
[TBL] [Abstract][Full Text] [Related]
12. Development of an animal model for prostate cancer cell metastasis to adult human bone.
Tsingotjidou AS; Zotalis G; Jackson KR; Sawyers C; Puzas JE; Hicks DG; Reiter R; Lieberman JR
Anticancer Res; 2001; 21(2A):971-8. PubMed ID: 11396190
[TBL] [Abstract][Full Text] [Related]
13. A mouse model of human breast cancer metastasis to human bone.
Kuperwasser C; Dessain S; Bierbaum BE; Garnet D; Sperandio K; Gauvin GP; Naber SP; Weinberg RA; Rosenblatt M
Cancer Res; 2005 Jul; 65(14):6130-8. PubMed ID: 16024614
[TBL] [Abstract][Full Text] [Related]
14. Antimestatic and antitumor activities of interleukin 10 in transfected human prostate PC-3 ML clones: Orthotopic growth in severe combined immunodeficient mice.
Stearns ME; Wang M
Clin Cancer Res; 1998 Sep; 4(9):2257-63. PubMed ID: 9748147
[TBL] [Abstract][Full Text] [Related]
15. The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer.
Yonou H; Ochiai A; Ashimine S; Maeda H; Horiguchi Y; Yoshioka K; Ogawa Y; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(9):999-1009. PubMed ID: 17440967
[TBL] [Abstract][Full Text] [Related]
16. The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone.
Gamradt SC; Feeley BT; Liu NQ; Roostaeian J; Lin YQ; Zhu LX; Sharma S; Dubinett SM; Lieberman JR
Anticancer Res; 2005; 25(1A):107-15. PubMed ID: 15816526
[TBL] [Abstract][Full Text] [Related]
17. An in vivo model of prostate carcinoma growth and invasion in bone.
Fisher JL; Schmitt JF; Howard ML; Mackie PS; Choong PF; Risbridger GP
Cell Tissue Res; 2002 Mar; 307(3):337-45. PubMed ID: 11904770
[TBL] [Abstract][Full Text] [Related]
18. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells.
Corey E; Quinn JE; Bladou F; Brown LG; Roudier MP; Brown JM; Buhler KR; Vessella RL
Prostate; 2002 Jun; 52(1):20-33. PubMed ID: 11992617
[TBL] [Abstract][Full Text] [Related]
19. SCID mouse lymphogenous metastatic model of human lung cancer constructed using orthotopic inoculation of cancer cells.
Miyoshi T; Kondo K; Ishikura H; Kinoshita H; Matsumori Y; Monden Y
Anticancer Res; 2000; 20(1A):161-3. PubMed ID: 10769649
[TBL] [Abstract][Full Text] [Related]
20. Use of a SCID mouse model to select for a more aggressive strain of prostate cancer.
Davies MR; Lee YP; Lee C; Zhang X; Afar DE; Lieberman JR
Anticancer Res; 2003; 23(3B):2245-52. PubMed ID: 12894499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
